Barclays
UTMD icon

Barclays’s Utah Medical Products UTMD Stock Holding History

Barclays’s Portfolio UTMD Stock Details UTMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$67.7K Sell
1,092
-4,527
-81% -$285K ﹤0.01% 4191
2025
Q4 		$314K Buy
5,619
+908
+19% +$52.6K ﹤0.01% 4105
2025
Q3 		$297K Sell
4,711
-772
-14% -$45.7K ﹤0.01% 4109
2025
Q2 		$312K Buy
5,483
+2,136
+64% +$116K ﹤0.01% 4029
2025
Q1 		$188K Sell
3,347
-1,936
-37% -$116K ﹤0.01% 4079
2024
Q4 		$325K Buy
5,283
+709
+16% +$45.8K ﹤0.01% 4076
2024
Q3 		$306K Buy
4,574
+3,118
+214% +$212K ﹤0.01% 4076
2024
Q2 		$97.3K Sell
1,456
-1,122
-44% -$76.4K ﹤0.01% 3922
2024
Q1 		$183K Sell
2,578
-2,179
-46% -$163K ﹤0.01% 4161
2023
Q4 		$401K Buy
4,757
+4,102
+626% +$340K ﹤0.01% 4014
2023
Q3 		$56.3K Sell
655
-30
-4% -$2.77K ﹤0.01% 3823
2023
Q2 		$63.8K Sell
685
-1,065
-61% -$100K ﹤0.01% 3737
2023
Q1 		$166K Buy
1,750
+825
+89% +$75.8K ﹤0.01% 3902
2022
Q4 		$93K Buy
925
+779
+534% +$71.1K ﹤0.01% 4266
2022
Q3 		$12K Sell
146
-27
-16% -$2.38K ﹤0.01% 4241
2022
Q2 		$15K Sell
173
-385
-69% -$32.8K ﹤0.01% 4510
2022
Q1 		$50K Sell
558
-3,599
-87% -$331K ﹤0.01% 4120
2021
Q4 		$415K Buy
4,157
+2,754
+196% +$281K ﹤0.01% 3282
2021
Q3 		$130K Buy
1,403
+967
+222% +$85.4K ﹤0.01% 3801
2021
Q2 		$37K Sell
436
-2,417
-85% -$209K ﹤0.01% 4278
2021
Q1 		$248K Buy
2,853
+1,752
+159% +$154K ﹤0.01% 3608
2020
Q4 		$93K Sell
1,101
-463
-30% -$39.5K ﹤0.01% 4164
2020
Q3 		$126K Sell
1,564
-323
-17% -$26.8K ﹤0.01% 4124
2020
Q2 		$167K Buy
+1,887
New +$169K ﹤0.01% 4197
2020
Q1 		– Sell
-4,189
Closed -$453K – 6469
2019
Q4 		$453K Buy
4,189
+1,766
+73% +$179K ﹤0.01% 4384
2019
Q3 		$232K Sell
2,423
-1,524
-39% -$142K ﹤0.01% 4860
2019
Q2 		$378K Buy
3,947
+2,957
+299% +$249K ﹤0.01% 4576
2019
Q1 		$88K Buy
990
+890
+890% +$78.3K ﹤0.01% 5466
2018
Q4 		$8K Sell
100
-1,824
-95% -$161K ﹤0.01% 6278
2018
Q3 		$181K Buy
1,924
+44
+2% +$4.2K ﹤0.01% 5089
2018
Q2 		$207K Sell
1,880
-328
-15% -$34.3K ﹤0.01% 4692
2018
Q1 		$218K Buy
2,208
+1,066
+93% +$95.1K ﹤0.01% 4760
2017
Q4 		$93K Buy
1,142
+463
+68% +$36.1K ﹤0.01% 5298
2017
Q3 		$50K Buy
679
+478
+238% +$34.4K ﹤0.01% 5352
2017
Q2 		$14K Buy
201
+185
+1,156% +$12.2K ﹤0.01% 5941
2017
Q1 		$1K Sell
16
-149
-90% -$9.38K ﹤0.01% 6639
2016
Q4 		$12K Buy
165
+21
+15% +$1.36K ﹤0.01% 5840
2016
Q3 		$9K Buy
144
+34
+31% +$2.16K ﹤0.01% 5839
2016
Q2 		$7K Buy
110
+10
+10% +$645 ﹤0.01% 5664
2016
Q1 		$6K Buy
+100
New +$5.9K ﹤0.01% 5636
2015
Q4 		– Sell
-19
Closed -$1K – 6604
2015
Q3 		$1K Sell
19
-40
-68% -$2.18K ﹤0.01% 6609
2015
Q2 		$3K Sell
59
-54
-48% -$3.04K ﹤0.01% 6702
2015
Q1 		$7K Sell
113
-101
-47% -$5.94K ﹤0.01% 6450
2014
Q4 		$13K Buy
214
+175
+449% +$9.69K ﹤0.01% 6575
2014
Q3 		$2K Sell
39
-25
-39% -$1.27K ﹤0.01% 7420
2014
Q2 		$3K Sell
64
-70
-52% -$3.59K ﹤0.01% 7301
2014
Q1 		$8K Sell
134
-289
-68% -$15.8K ﹤0.01% 7035
2013
Q4 		$24K Buy
423
+106
+33% +$5.82K ﹤0.01% 6603
2013
Q3 		$18K Sell
317
-200
-39% -$10.9K ﹤0.01% 6560
2013
Q2 		$28K Buy
+517
New +$24.3K ﹤0.01% 6667

Other funds holding UTMD

BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MA
Minerva Advisors Bala Cynwyd, Pennsylvania $155M AUM 35.49% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Barclays's UTMD Position: Q1 2026 in Review

Barclays reduced its Utah Medical Products (UTMD) stake by 81% in Q1 2026, selling an estimated $285K and leaving 1,092 shares worth $67.7K. The position accounts for ﹤0.01% of the portfolio, ranked #4191.

Barclays first reported a position in UTMD in Q2 2013 and has held it in 50 quarters since. The position peaked at $453K in Q4 2019. 119 funds tracked by Wall St. Rank hold UTMD as of Q1 2026.

  • Barclays held 1,092 shares of Utah Medical Products worth $67.7K as of Q1 2026.
  • Barclays sold 4,527 Utah Medical Products shares in Q1 2026, an estimated $285K.
  • Utah Medical Products made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #4191 holding.
  • Barclays first reported a position in Utah Medical Products in Q2 2013 and has held it in 50 quarters since.
  • Barclays's Utah Medical Products position peaked at $453K in Q4 2019.
  • 119 funds tracked by Wall St. Rank held Utah Medical Products as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.